Pulmonary rehabilitation 2007: from bench to practice and back.

COPD is a disease that is not confined to the airways and the lungs, but also produces systemic consequences. Muscle weakness is one of these. It is produced by a multitude of factors including deconditioning, systemic inflammation, oxidative stress, nutritional imbalance, reduced anabolic status, systemic corticosteroids, hypoxemia, hypercapnia, electrolyte disturbances, cardiac failure. The most important factors appear to be inactivity and systemic inflammation. Inactivity was shown to be present in patients with COPD from early in the course of the disease on. Systemic inflammation was shown to be predominantly present during COPD exacerbations. IL-6 has the propensity to reduce muscle function in experimental animals. At present there is no evidence of local production of cytokines in the muscle in patients with COPD. Muscle weakness is also important in the clinical course of the disease as it is associated with exercise intolerance, reduced quality of life, enhanced utilization of health care resources and reduced survival. Rehabilitation is the best treatment for muscle weakness and deconditioning in patients with COPD. Indeed, it is the intervention with the largest effect on health status and exercise capacity in these patients. Several factors that may enhance the effects of rehabilitation have been studied. These include: growth hormone/ IGF-I, anabolic steroids, clenbuterol, creatine, anti-cytokine treatment, erythropoietin, oxygen, non-invasive mechanical ventilation and electrical stimulation. Recently, the potential of protease-inhibitors in reversing deconditioning-induced muscle dysfunction was demonstrated. Adjuncts are potentially particularly useful in patients who do not respond to a rehabilitation programme. Analysis of large d-bases demonstrated that about one third of the patients does not respond to rehabilitation. A follow-up study suggests that decline in exercise capacity after a rehabilitation programme is particularly present in these patients and not in the patients with a clear initial response. A better understanding of the factors controlling the response to rehabilitation, may lead to significant advances in this field.

[1]  Nawal Al-Ghamdi Peripheral Muscle Dysfunction in Chronic Obstructive Pulmonary Disease@@@الاختلال الوظيفي للعضلات الطرفية في داء الرئة الانسدادي المزمن , 2009 .

[2]  M. Decramer,et al.  Markers of inflammation and disuse in vastus lateralis of chronic obstructive pulmonary disease patients , 2007, European journal of clinical investigation.

[3]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[4]  N. Anthonisen,et al.  Mortality in COPD: role of comorbidities , 2006, European Respiratory Journal.

[5]  R. Stockley,et al.  Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity – a common inflammatory phenotype? , 2006, Respiratory research.

[6]  Sung Soon Lee,et al.  Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease , 2006 .

[7]  Thierry Troosters,et al.  Physical activity and hospitalization for exacerbation of COPD. , 2006, Chest.

[8]  F. Maltais,et al.  The metabolic syndrome in patients with chronic obstructive pulmonary disease. , 2005, Journal of cardiopulmonary rehabilitation.

[9]  D. Sin,et al.  The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. , 2005, Chest.

[10]  Thierry Troosters,et al.  Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. , 2005, American journal of respiratory and critical care medicine.

[11]  A. Anzueto,et al.  One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. , 2005, Pulmonary pharmacology & therapeutics.

[12]  M. Decramer,et al.  Assessment of progression of COPD: report of a workshop held in Leuven, 11–12 March 2004 , 2005, Thorax.

[13]  M. Decramer,et al.  Interleukin-6 Causes Myocardial Failure and Skeletal Muscle Atrophy in Rats , 2005, Circulation.

[14]  A. Buist,et al.  The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design. , 2005, COPD.

[15]  A. Ionescu,et al.  Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.

[16]  R. Casaburi,et al.  Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.

[17]  M. Decramer,et al.  Clinical Trial Design Considerations in Assessing Long‐Term Functional Impacts of Tiotropium in COPD: The Uplift Trial , 2004, COPD.

[18]  E. Wouters,et al.  A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. , 2003, Chest.

[19]  Margareta Emtner,et al.  Benefits of supplemental oxygen in exercise training in nonhypoxemic chronic obstructive pulmonary disease patients. , 2003, American journal of respiratory and critical care medicine.

[20]  M. Decramer,et al.  CHRONIC OBSTRUCTIVE PULMONARY DISEASE Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I , 2003 .

[21]  F. Maltais,et al.  Contractile leg fatigue after cycle exercise: a factor limiting exercise in patients with chronic obstructive pulmonary disease. , 2003, American journal of respiratory and critical care medicine.

[22]  D. Mannino,et al.  Low lung function and incident lung cancer in the United States: data From the First National Health and Nutrition Examination Survey follow-up. , 2003, Archives of internal medicine.

[23]  François Maltais,et al.  Exercise-induced quadriceps oxidative stress and peripheral muscle dysfunction in patients with chronic obstructive pulmonary disease. , 2003, American journal of respiratory and critical care medicine.

[24]  D. Sin,et al.  The risk of osteoporosis in Caucasian men and women with obstructive airways disease. , 2003, The American journal of medicine.

[25]  C. Rochester,et al.  Randomised controlled trial of transcutaneous electrical muscle stimulation of the lower extremities in patients with chronic obstructive pulmonary disease , 2002, Thorax.

[26]  M. Polkey,et al.  Proportional assist ventilation as an aid to exercise training in severe chronic obstructive pulmonary disease , 2002, Thorax.

[27]  Y. Lacasse,et al.  Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[28]  John E Connett,et al.  Smoking and lung function of Lung Health Study participants after 11 years. , 2002, American journal of respiratory and critical care medicine.

[29]  S. Ward,et al.  Home based neuromuscular electrical stimulation as a new rehabilitative strategy for severely disabled patients with chronic obstructive pulmonary disease (COPD) , 2002, Thorax.

[30]  D. O’Donnell,et al.  Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[31]  K. Yarasheski,et al.  Resistance exercise decreases skeletal muscle tumor necrosis factor α in frail elderly humans , 2001 .

[32]  M. Decramer,et al.  Exercise training in COPD: how to distinguish responders from nonresponders. , 2001, Journal of cardiopulmonary rehabilitation.

[33]  K. Yarasheski,et al.  Resistance exercise decreases skeletal muscle tumor necrosis factor alpha in frail elderly humans. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  Z. Nahas,et al.  Functional impairment in COPD patients: the impact of anxiety and depression. , 2000, Psychosomatics.

[35]  D. Coultas,et al.  Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. , 2000, Archives of internal medicine.

[36]  T L Petty,et al.  Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. , 2000, Archives of internal medicine.

[37]  E. Wouters,et al.  Different patterns of chronic tissue wasting among patients with chronic obstructive pulmonary disease. , 1999, Clinical nutrition.

[38]  M. Decramer,et al.  Systolic ventricular dysfunction causes selective diaphragm atrophy in rats. , 1998, American journal of respiratory and critical care medicine.

[39]  F. Forastiere,et al.  Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. , 1997, The European respiratory journal.

[40]  M. Decramer,et al.  Muscle weakness is related to utilization of health care resources in COPD patients. , 1997, The European respiratory journal.

[41]  M. Decramer,et al.  Peripheral muscle weakness contributes to exercise limitation in COPD. , 1996, American journal of respiratory and critical care medicine.

[42]  N. Jones,et al.  Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. , 1995, American journal of respiratory and critical care medicine.

[43]  M. Decramer,et al.  Corticosteroids contribute to muscle weakness in chronic airflow obstruction. , 1994, American journal of respiratory and critical care medicine.

[44]  D. Mancini,et al.  Respiratory Muscle Function and Dyspnea in Patients With Chronic Congestive Heart Failure , 1992, Circulation.

[45]  P. Macklem,et al.  Contractile properties of the human diaphragm during chronic hyperinflation. , 1991, The New England journal of medicine.

[46]  W. Kannel,et al.  Mortality associated with respiratory function and symptoms in advanced age. The Framingham Study. , 1989, The American review of respiratory disease.

[47]  M. Aubier,et al.  Effect of Hypophosphatemia on Diaphragmatic Contractility in Patients with Acute Respiratory Failure , 1986 .

[48]  D. F. Rochester,et al.  Determinants of maximal inspiratory pressure in chronic obstructive pulmonary disease. , 2015, The American review of respiratory disease.

[49]  C. Roussos,et al.  Diaphragm in emphysematous hamsters: sarcomere adaptability. , 1983, Journal of applied physiology: respiratory, environmental and exercise physiology.

[50]  B. Burrows,et al.  Course and prognosis of chronic obstructive lung disease. A prospective study of 200 patients. , 1969, The New England journal of medicine.